🟢 Definium Therapeutics is trading 22.22% up in pre-market after Voyage Phase 3 met primary endpoint

Definium Therapeutics is trading at $50.00 (+22.22%) after Voyage Phase 3 met its primary endpoint in generalized anxiety disorder.

• DT120 ODT delivered a 5.4-point placebo-adjusted HAM-A improvement at Week 12, with p<0.0001.
• Results met key secondary endpoints, showed a 43% response rate versus 16% for placebo, and revealed no new safety signals.
• Broader pre-market indices were modestly higher.